Cargando…
Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study
BACKGROUND: The predictive value of serum neurofilament light chain (sNfL) on long-term prognosis in multiple sclerosis (MS) is still unclear. OBJECTIVE: Investigate the relation between sNfL levels over a 2-year period in patients with relapsing-remitting MS, and clinical disability and grey matter...
Autores principales: | Lie, Ingrid Anne, Kaçar, Sezgi, Wesnes, Kristin, Brouwer, Iman, Kvistad, Silje S, Wergeland, Stig, Holmøy, Trygve, Midgard, Rune, Bru, Alla, Edland, Astrid, Eikeland, Randi, Gosal, Sonia, Harbo, Hanne F, Kleveland, Grethe, Sørenes, Yvonne S, Øksendal, Nina, Varhaug, Kristin N, Vedeler, Christian A, Barkhof, Frederik, Teunissen, Charlotte E, Bø, Lars, Torkildsen, Øivind, Myhr, Kjell-Morten, Vrenken, Hugo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304101/ https://www.ncbi.nlm.nih.gov/pubmed/35649699 http://dx.doi.org/10.1136/jnnp-2021-328568 |
Ejemplares similares
-
The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis
por: Lie, Ingrid Anne, et al.
Publicado: (2022) -
Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023) -
Association of adverse childhood experiences with the development of multiple sclerosis
por: Eid, Karine, et al.
Publicado: (2022) -
Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT
por: Kvistad, Silje Agnethe Stokke, et al.
Publicado: (2022) -
Humoral immunity to SARS-CoV-2 mRNA vaccination in multiple sclerosis: the relevance of time since last rituximab infusion and first experience from sporadic revaccinations
por: König, Marton, et al.
Publicado: (2023)